Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

MadeMed vs Potere Health MD

Two GLP-1 desks, one scoreboard. We put MadeMed and Potere Health MD head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 8 · Grade B

MadeMed

Visit MadeMed Full brief →
vs
No. 264 · Grade C

Potere Health MD

Visit Potere Health MD Full brief →

The verdict

MadeMed takes this head-to-head.

MadeMed scores 86 to 64 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.

That doesn't make Potere Health MD a bad call — it's best for readers who want utah residents wanting low-cost, physician-led glp-1 weight loss without a subscription. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
92
48
Supply Reliability
84
77
Transparency
94
48
Access Breadth
76
56
Clinical Oversight
84
87
Track Record
82
82
MadeMedBrief Score 86 · 64Potere Health MD

Price, coverage & the tracker

MadeMedPotere Health MD
Brief Score86/100 (B)64/100 (C)
Semaglutide$239/mo injectable · $219/mo sublingual (quarterly)From $80/mo (starting dose, compounded)
Tirzepatide$399/mo injectable · $299/mo sublingual (quarterly)From $135/mo (starting dose, compounded)
Coverage40 states1 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.

Potere Health MD: New to the tracker on 1 August 2026. The published line reads From $80/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.